vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and LendingTree, Inc. (TREE). Click either name above to swap in a different company.
LendingTree, Inc. is the larger business by last-quarter revenue ($327.3M vs $177.4M, roughly 1.8× Pacira BioSciences, Inc.). LendingTree, Inc. runs the higher net margin — 5.3% vs 1.6%, a 3.6% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs 2.4%). Over the past eight quarters, LendingTree, Inc.'s revenue compounded faster (24.8% CAGR vs -0.2%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
LendingTree, Inc. is an online lending marketplace, founded in 1996 and headquartered in Charlotte, North Carolina. The business platform allows potential borrowers to connect with multiple loan operators to find optimal terms for loans, credit cards, deposit accounts, insurance, etc. LendingTree allows borrowers to shop and compare competitive rates and terms across an array of financial products. Other additional services include financing tools, comparative loan searches and borrowing info...
PCRX vs TREE — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $327.3M |
| Net Profit | $2.9M | $17.3M |
| Gross Margin | — | 100.0% |
| Operating Margin | 3.9% | 9.5% |
| Net Margin | 1.6% | 5.3% |
| Revenue YoY | 5.0% | 2.4% |
| Net Profit YoY | — | 239.5% |
| EPS (diluted) | $0.07 | $1.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | $327.3M | ||
| Q4 25 | $196.9M | $319.7M | ||
| Q3 25 | $179.5M | $307.8M | ||
| Q2 25 | $181.1M | $250.1M | ||
| Q1 25 | $168.9M | $239.7M | ||
| Q4 24 | $187.3M | $261.5M | ||
| Q3 24 | $168.6M | $260.8M | ||
| Q2 24 | $178.0M | $210.1M |
| Q1 26 | $2.9M | $17.3M | ||
| Q4 25 | — | $144.7M | ||
| Q3 25 | $5.4M | $10.2M | ||
| Q2 25 | $-4.8M | $8.9M | ||
| Q1 25 | $4.8M | $-12.4M | ||
| Q4 24 | — | $7.5M | ||
| Q3 24 | $-143.5M | $-58.0M | ||
| Q2 24 | $18.9M | $7.8M |
| Q1 26 | — | 100.0% | ||
| Q4 25 | 79.5% | 29.2% | ||
| Q3 25 | 80.9% | 30.7% | ||
| Q2 25 | 77.4% | 34.0% | ||
| Q1 25 | 79.7% | 32.9% | ||
| Q4 24 | 78.7% | 33.6% | ||
| Q3 24 | 76.9% | 30.2% | ||
| Q2 24 | 75.1% | 34.5% |
| Q1 26 | 3.9% | 9.5% | ||
| Q4 25 | 1.2% | 7.0% | ||
| Q3 25 | 3.5% | 9.3% | ||
| Q2 25 | 4.7% | 8.4% | ||
| Q1 25 | 1.2% | -3.0% | ||
| Q4 24 | 13.2% | 6.9% | ||
| Q3 24 | -82.8% | 3.8% | ||
| Q2 24 | 15.9% | 4.6% |
| Q1 26 | 1.6% | 5.3% | ||
| Q4 25 | — | 45.2% | ||
| Q3 25 | 3.0% | 3.3% | ||
| Q2 25 | -2.7% | 3.5% | ||
| Q1 25 | 2.8% | -5.2% | ||
| Q4 24 | — | 2.9% | ||
| Q3 24 | -85.1% | -22.2% | ||
| Q2 24 | 10.6% | 3.7% |
| Q1 26 | $0.07 | $1.22 | ||
| Q4 25 | $0.05 | $10.32 | ||
| Q3 25 | $0.12 | $0.73 | ||
| Q2 25 | $-0.11 | $0.65 | ||
| Q1 25 | $0.10 | $-0.92 | ||
| Q4 24 | $0.38 | $0.54 | ||
| Q3 24 | $-3.11 | $-4.34 | ||
| Q2 24 | $0.39 | $0.58 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $85.5M |
| Total DebtLower is stronger | — | $390.9M |
| Stockholders' EquityBook value | $653.9M | $304.7M |
| Total Assets | $1.2B | $863.9M |
| Debt / EquityLower = less leverage | — | 1.28× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | $85.5M | ||
| Q4 25 | $238.4M | $81.1M | ||
| Q3 25 | $246.3M | $68.6M | ||
| Q2 25 | $445.9M | $149.1M | ||
| Q1 25 | $493.6M | $126.4M | ||
| Q4 24 | $484.6M | $106.6M | ||
| Q3 24 | $453.8M | $96.8M | ||
| Q2 24 | $404.2M | $66.8M |
| Q1 26 | — | $390.9M | ||
| Q4 25 | $372.2M | $387.7M | ||
| Q3 25 | $376.7M | $388.4M | ||
| Q2 25 | $580.5M | $385.1M | ||
| Q1 25 | $583.4M | $387.7M | ||
| Q4 24 | $585.3M | $344.1M | ||
| Q3 24 | — | $346.2M | ||
| Q2 24 | — | $467.7M |
| Q1 26 | $653.9M | $304.7M | ||
| Q4 25 | $693.1M | $286.8M | ||
| Q3 25 | $727.2M | $132.4M | ||
| Q2 25 | $757.8M | $118.1M | ||
| Q1 25 | $798.5M | $103.7M | ||
| Q4 24 | $778.3M | $108.8M | ||
| Q3 24 | $749.6M | $94.3M | ||
| Q2 24 | $879.3M | $145.8M |
| Q1 26 | $1.2B | $863.9M | ||
| Q4 25 | $1.3B | $855.7M | ||
| Q3 25 | $1.3B | $759.9M | ||
| Q2 25 | $1.5B | $835.8M | ||
| Q1 25 | $1.6B | $777.1M | ||
| Q4 24 | $1.6B | $767.7M | ||
| Q3 24 | $1.5B | $787.2M | ||
| Q2 24 | $1.6B | $802.2M |
| Q1 26 | — | 1.28× | ||
| Q4 25 | 0.54× | 1.35× | ||
| Q3 25 | 0.52× | 2.93× | ||
| Q2 25 | 0.77× | 3.26× | ||
| Q1 25 | 0.73× | 3.74× | ||
| Q4 24 | 0.75× | 3.16× | ||
| Q3 24 | — | 3.67× | ||
| Q2 24 | — | 3.21× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
TREE
| Insurance segment | $221.9M | 68% |
| Consumer segment | $66.3M | 20% |
| Home segment | $39.1M | 12% |
